Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Vimseltinib |
Synonyms | |
Therapy Description |
Vimseltinib (DCC-3014) inhibits CSF1R, potentially resulting in increased anti-tumor immune response in combination with other agents (PMID: 29679908, PMID: 34433663). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Vimseltinib | DCC-3014|DCC3014|DCC 3014|DP-6865 | CSF1R Inhibitor 28 | Vimseltinib (DCC-3014) inhibits CSF1R, potentially resulting in increased anti-tumor immune response in combination with other agents (PMID: 29679908, PMID: 34433663). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05059262 | Phase III | Vimseltinib | Phase 3 Study of Vimseltinib for Tenosynovial Giant Cell Tumor (MOTION) | Active, not recruiting | USA | POL | NOR | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | AUS | 1 |
NCT03069469 | Phase I | Vimseltinib | Study of DCC-3014 in Patients With Advanced Malignancies | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | CAN | AUS | 0 |